section name header

Classifications

Therapeutic Classification: antihyroid agents

Pharmacologic Classification: iodine containing agents

Indications

REMS


Action

  • Rapidly inhibits the release and synthesis of thyroid hormones.
  • Decreases the vascularity of the thyroid gland.
  • Decreases thyroidal uptake of radioactive iodine following radiation emergencies or administration of radioactive isotopes of iodine.
  • Iodine is a necessary component of thyroid hormone.
Therapeutic effects:

Pharmacokinetics

Absorption: Converted in the GI tract and enters the circulation as iodine; also absorbed through skin and lungs; may also be obtained via recycling of iodothyronines.

Distribution: Concentrates in the thyroid gland and muscle; also found in skin, skeleton, breasts, and hair. Readily crosses the placenta; enters breast milk.

Metabolism/Excretion: Taken up by the thyroid gland, then eliminated via kidneys, liver, skin, lungs, and intestines.

Half-Life: Unknown.

Time/Action Profile

(effects on thyroid)

ROUTEONSETPEAKDURATION
PO24 hr10–15 daysvariable



Radiation protection lasts 24 hr.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: GI BLEEDING, diarrhea, nausea, vomiting

Derm: acneiform eruptions

Endo: hypothyroidism, goiter, hyperthyroidism

F and E: hyperkalemia

Neuro: tingling, confusion, weakness

MS: joint pain

Misc: hypersensitivity, iodism

Interactions

Drug-drug:

Route/Dosage

Preparation for Thyroidectomy

Hyperthyroidism

Radiation Protectant to Radioactive Isotopes of Iodine

Reduction of Thyroid Cancer after Nuclear Accident

Availability

Potassium Iodide

Strong Iodine Solution

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

potassium iodide: Pima, SSKI, ThyroSafe, ThyroShield,

strong iodine solution: Lugol’s solution

Pot. Nursing Diagnoses